AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04937283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lobectomy with hilar and mediastinal lymph node dissection
Description: Lobectomy with hilar and mediastinal lymph node dissection is performed. Segmentectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
Study NCT02929238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polypropylene Suture Right Side
Description: Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
Study NCT02929238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polypropylene Suture Left Side
Description: Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
Study NCT01962272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly nutritional counseling
Description: The counseling included assessment of food intake, advice about improvement, motivation and specific food plans, as well as motivation to comply to the recommended dose of Forticare®.
Study NCT01962272 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Forticare®.
Study NCT03716661 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ORIF
Description: Open Reduction Internal Fixation
Study NCT02212769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50mg
Description: Losartan 50mg once daily for 7 days
Study NCT02212769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M 1200mg and Losartan 50mg
Description: Losartan 50mg 1 Tablet once daily and DW1029M 300mg 2 Tablets b.i.d. for 7days
Study NCT02088567 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total Knee Arthroplasty
Description: Total knee arthroplasty, per the usual practice of the physician.
Study NCT02088567 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty
Description: Total knee arthroplasty, per the usual practice of the physician.
Study NCT04483713 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Workshop plus J. H. N. EBP Guide Tools
Description: In addition to the workshop. It will follow the same molds as the case of group Educational Workshop plus the Johns Hopkins Nursing Evidence-based Practice guide tools since the beginning of this practical class, when the participant will receive a description of a problem as a basis for elaborating their clinical question, and thus, move on to the next stage.~The tools will be offered in the case of this group: question development, evidence level and quality guide, research evidence assessment tool, individual evidence tool, evidence synthesis and recommendation tool, action planning tool and tool dissemination.
Study NCT02981719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: simultaneous gemcitabine and irreversible electroporation
Description: gemcitabine intravenous infusion prior to irreversible electroporation treatment
Study NCT02765191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasma expansion with Ringer's Acetate
Description: 7,5 ml/kg mL Ringer's acetate during 5-10 minutes will be administered intravenously
Study NCT02088567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of dHACM
Description: Application of dHACM at end of procedure before closing wound between the underlying fascia and the overlying skin layers to reduce scar formation
Study NCT01089790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutogliptin
Description: 400 mg tablet, once daily
Study NCT01089790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg capsule (each capsule contains two 50-mg tablets), once daily
Study NCT03623009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An article meant to trigger certain psychosocial behaviors
Description: An article meant to trigger certain psychosocial behaviors is administered to the intervention arm prior to laparoscopic skills assessment.
Study NCT03731065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fructose-maltodextrin
Description: Fructose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
Study NCT03623009 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: a neutral article
Description: The control arm will receive a neutral article prior to completing the assessment.
Study NCT02204488 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Joint Arthroplasty
Description: Total Joint Arthroplasty with device: Maïa® trapezio-metacarpal joint prosthesis, Groupe Lépine, Genay, France
Study NCT02981719 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: irreversible electroporation
Description: percutaneous irreversible electroporation was performmed for locally advaanced pancreatic cancer.
Study NCT03525015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A decision aid booklet about cataract surgery choice
Description: Potential participants receive a decision aid booklet with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
Study NCT03525015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: An usual booklet about cataract and cataract surgery
Description: Potential participants receive an usual booklet with information about cataract and cataract surgery, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
Study NCT04211701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective Tissue Massage
Description: Connective tissue massage (CTM) will be applied to the lumbo-sacral region, lower thoracic, scapular and interscapular regions. Three to five pulling will be applied during massage. The treatment will be administered for four weeks, five days a week.
Study NCT02204488 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trapeziectomy
Description: Trapeziectomy
Study NCT04135014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
Study NCT04135014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: intranasal dexmedetomidine 2µg.kg-1 approximately 30-40 mins before surgery using a computer-generated random number table.
Study NCT04135014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam and Dexmedetomidine
Description: oral midazolam 0.5mg.kg-1 and intranasal dexmedetomidine 1ug.kg-1 approximately 30-40 mins before surgery using a computer-generated random number table.
Study NCT04211701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Classical Massage
Description: Classic massage (CM) will be applied to the lower back and upper back while the patient is lying in the prone position. Three stroking will be applied during massage.The treatment will be administered for four weeks, five days a week.
Study NCT03553407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser - Pulse
Description: The laser will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
Study NCT03553407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser - continuous
Description: The laser will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
Study NCT03553407 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low Level Laser - placebo
Description: placebo will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
Study NCT01142310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine will be initiated at 25 mg/day and upwardly titrated to a dose of 400 mg/day over 10 weeks.
Study NCT01142310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00789893 — intervention group
Intervention type: DEVICE
Intervention: Vaginal Dilator
Description: Participants will be instructed to use the dilators 3 times per week, regardless of frequency of sexual intercourse. At 5 time points, data will be collected to determine vaginal dilator size, grade vaginal stenosis \& assess vaginal symptoms. 1)Baseline: patient self-assessment following consultation up until the end of the first week of radiation 2)Post-radiation: patient self-assessment one month ± 2 weeks follow-up from last day of radiation 3)Post-radiation: 3 month ± 4 weeks follow-up from initiation of dilator use 4)Post-radiation: 6 month ± 4 weeks follow-up from initiation of dilator use 5)Post-radiation: 12 months ± 4 weeks follow-up from initiation of dilator use. At the 1st \& 2nd time points, the nurse will telephone the patient to retrieve her responses. The 1st phone call will occur between the time following consultation up until the end of the first week of radiation, \& the 2nd will be one month ± 2 weeks from last day of radiation.
Study NCT02730572 — intervention group
Intervention type: DRUG
Intervention: Concerta
Description: This is an observational study. Participants who have been on Concerta for at least 60 days will be observed.
Study NCT02730572 — intervention group
Intervention type: DRUG
Intervention: Concerta AG formulation
Description: This is an observational study. Participants who have been on Concerta for at least 60 days and switch to authorized generic will be observed.
Study NCT02730572 — intervention group
Intervention type: DRUG
Intervention: Concerta EG formulation
Description: This is an observational study. Participants who have been on Concerta for at least 60 days and switch to equivalent generic will be observed.
Study NCT01770483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitazoxanide
Description: nitazoxanide 500mg twice daily
Study NCT01770483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional interferon alfa
Description: Inj interferon 3 Million International Units thrice weekly
Study NCT01770483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional interferon alfa
Description: Inj interferon 3 Million International Units thrice weekly
Study NCT01770483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: ribazole
Study NCT01770483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: ribazole
Study NCT01540708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SERETIDE Rotacaps
Description: The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
Study NCT01540708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SERETIDE Diskus
Description: The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
Study NCT02479256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Description: Women will receive one tablet of clomiphene citrate oral tablets 50 mg (Clomid®, aventis/Egypt) twice daily 12 hours apart (total dose 100 mg daily) from the 3rd day of the menses for 5 days, for only one menstrual cycle.
Study NCT03731065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose-maltodextrin hydrogel
Description: Fructose plus maltodextrin in a ratio of 1:1.4, encapsulated in an alginate-pectin hydrogel diluted in water to produce a 16% carbohydrate solution.
Study NCT03731065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose-maltodextrin
Description: Glucose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
Study NCT01406509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5ml/dose for a person
Description: group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0
Study NCT01406509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5ml/dose for a person
Description: group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0, 28
Study NCT03432819 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Siempre Seguiré
Description: A culturally congruent CBT group intervention for HIV-positive LMSM, to include strategies for ART adherence and retention in HIV care.
Study NCT01636050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: squat exercise training
Description: Intervention may include squat exercise for 8 weeks
Study NCT03812224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered by subcutaneous injection once a month
Study NCT03812224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erenumab
Description: Administered by subcutaneous injection once a month
Study NCT03812224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection once a month
Study NCT02825745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Betashot
Description: Betashot is a Food for Special Medical Purposes (FSMP). Suitable for use from 3 years of age.
Study NCT01344213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Oral single-dose of pregabalin (150 mg) and placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
Study NCT01344213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Oral single-dose of celecoxib (400 mg) and placebo(C)1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
Study NCT02404428 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard broccoli soup
Description: 300g/week of standard broccoli soup consumed for a period of six months delivering standard level of glucoraphanin (sulforaphane precursor)
Study NCT02404428 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beneforte extra broccoli soup
Description: 300g/week of beneforte extra broccoli soup consumed for a period of six months delivering enriched levels of glucoraphanin (sulforaphane precursor)
Study NCT02706197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OxyChip
Description: The OxyChip is an investigational device to assess oxygen level in tissues, when measured with Electron Paramagnetic Resonance (EPR).
Study NCT01551524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mPEG-r-crisantaspase
Description: IV infusion over 60 minutes of mPEG-r-crisantaspase given once every two or four weeks for two administrations. Based on non-clinical data, 500IU/m2 has been selected as the starting dose. Dose selection will proceed based upon safety and pharmacokinetic data but escalation will not exceed 100%
Study NCT01610986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose-fructose
Description: 0.8 g/h glucose and 0.5 g/h fructose during training
Study NCT01610986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water
Description: Only water intake during training
Study NCT05004948 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: The first group conducted a resistance exercise program (REP, 50-60% of 1RM, for 40-50 min) combined with metformin, the second group conducted an aerobic exercise program (AEP, 50-70% maxHR, for 40-50 min) combined with metformin, and the third group received only metformin without exercise intervention (Met group). The study program was conducted thrice weekly for consecutive twelve weeks.
Study NCT05390658 — intervention group
Intervention type: OTHER
Intervention: Not application
Description: Not application
Study NCT03127423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid ablation
Description: This intervention includes totally thoracoscopic surgical ablation and percutaneous catheter ablation simultaneously.
Study NCT03127423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopic surgical ablation
Description: This intervention only includes totally thoracoscopic surgical ablation without percutaneous catheter ablation.
Study NCT03964792 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DREPAGLOBE drug product
Description: Each patient will receive a single IV infusion of DREPAGLOBE drug product
Study NCT03035682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Media Group
Description: The intervention group will receive traditional PT services deemed clinically appropriate via examination plus home exercise prescription augmented via a mobile health application. The augmented media group will receive digital exercise prescription via a mobile health application source (Physitrack) that includes: high definition video and pictures, education material and written instruction, reminder notification and in-app logging of completion.
Study NCT03035682 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Group
Description: The Traditional Group will receive traditional PT services deemed clinically appropriate via examination plus traditional home exercise prescription.
Study NCT03926988 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NeVa Stent Retriever
Description: mechanical neurothrombectomy
Study NCT03350555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Additioned Endoscopy
Description: To evaluate the use of additioned endoscopy in ERCP treatment.
Study NCT03090672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Normal Saline IV delivery
Study NCT03090672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Stromal Vascular Fraction
Description: tSVF
Study NCT03090672 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: PRP
Study NCT03090672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cellular Stromal Vascular Fraction
Description: cSVF